Departmental Highlights
Home >  Cancer (Oncology) >  Services and Treatments >  Departmental Highlights
Print

Services and Treatments

Departmental Highlights

Montefiore Einstein Center for Cancer Care Earns Top Honors for Outstanding Care and Research

TOP HONORS EARNED BY MONTEFIORE EINSTEIN CENTER FOR CANCER CARE

Montefiore Einstein Center for Cancer Care has joined an elite group of cancer programs that have earned a Three-Year Accreditation with Gold Level Commendation from the Commission on Cancer (CoC) of the American College of Surgeons.

Montefiore also received the CoC's highest honor—the Outstanding Achievement Award—for quality care. This designation was awarded to only six percent of CoC-designated cancer programs across the country. These honors reflect outstanding clinical care and research, unparalleled social and emotional support, and outcomes for patients. Learn more>


Montefiore-Einstein Physician Leads Global Practice-Changing Study in Early Stage Breast Cancer

Joseph Sparano, MDJoseph Sparano, MD, Associate Director of Albert Einstein Cancer Center, and Associate Chairman, Oncology, Montefiore Health System, presented his groundbreaking research findings from the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The trial was supported by the National Cancer Institute (NCI), part of the National Institutes of Health, and designed and led by the ECOG-ACRIN Cancer Research Group, of which Dr. Sparano is vice chair.

This research, resulting from a 12-year study, showed that for women with a specific type of breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than treatment with hormone therapy alone. The new data will help inform treatment decisions for many women with early-stage breast cancer.

"The new results from TAILORx give clinicians high-quality data to inform personalized treatment recommendations for women," said Dr. Sparano, who was lead author on the research. "These data confirm that using a 21-gene expression test to assess the risk of cancer recurrence can spare women unnecessary treatment if the test indicates that chemotherapy is not likely to provide benefit."

For more information on Dr. Sparano and the TAILORx trial, visit https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy.


Montefiore Partners with New York Cancer Providers to Open Proton Therapy Center in Manhattan

The New York Proton Regional Center—a pioneering collaboration between Montefiore, Memorial Sloan Kettering Cancer Center, and Mount Sinai Health System—will open in East Harlem in 2019 to offer Proton-beam therapy, a powerful alternative to traditional radiation treatment.

The new Center will provide specialized radiation treatment to children and adults with tumors extremely close to highly sensitive structures, such as the base of the brain and the heart. This pioneering center, recently featured in the New York Times and Crain's New York Business, is the first of its kind in New York State and one of only 25 such facilities nationwide.

Proton-beam therapy is an alternative to traditional radiation, allowing physicians to deliver full therapeutic doses of radiation while sparing surrounding healthy tissues and organs. Evidence supports its use in pediatric cancers and areas where extreme precision is necessary to treat tumors, such as the central nervous system, head and neck, and eyes.

Shalom Kalnicki, MD, Chair, Radiation Oncology, stated in the Crain's article, "Pediatrics is the biggest need."


Montefiore Einstein Center for Cancer Care Deploys APOTECAchemo Robotic System

Montefiore Einstein Center for Cancer Care recently deployed the APOTECAchemo robotic system, which is designed to deliver unparalleled accuracy and increased safety for patients.

APOTECAchemo empowers our Pharmacy through robotic technology that automates the drug compounding process. This technology is found at only five major academic medical centers nationwide.

"Our investment in leading-edge devices illustrates our commitment to providing our patients with the most advanced cancer treatments," says Roman Perez-Soler, MD, Chairman, Oncology; Chief, Division of Medical Oncology and Deputy Director, Albert Einstein Cancer Center, Montefiore, and Guttman Professor of Medicine and Molecular Pharmacology, Einstein.

The APOTECAchemo consists of a robotic automation and information platform to prepare intravenous doses of chemotherapy. Risks to healthcare workers associated with compounding hazardous drugs are minimized while patient safety is improved.

Montefiore's APOTECAchemo makes every step of the process programmable, controllable, traceable and accountable. Patients benefit from the high degree of accuracy of the system, and built-in sterility measures that increase safety.